Effects of a Novel Bradykinin B1 Receptor Antagonist and Angiotensin II Receptor Blockade on Experimental Myocardial Infarction in Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Dec 14

PMID 23236443

Citations 5

Authors

Dongmei Wu

Xinchun Lin

Christian Bernloehr

Tobias Hildebrandt

Henri Doods

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the present study was to evaluate the cardiovascular effects of the novel bradykinin B1 receptor antagonist BI-113823 following myocardial infarction (MI) and to determine whether B1 receptor blockade alters the cardiovascular effects of an angiotensin II type 1 (AT1) receptor antagonist after MI in rats.

Methodology/principal Findings: Sprague Dawley rats were subjected to permanent occlusion of the left descending coronary artery. Cardiovascular function was determined at 7 days post MI. Treatment with either B1 receptor antagonist (BI-113823) or AT1 receptor antagonist (irbesartan) alone or in combination improved post-MI cardiac function as evidenced by attenuation of elevated left ventricular end diastolic pressure (LVEDP); greater first derivative of left ventricular pressure (± dp/dt max), left ventricle ejection fraction, fractional shorting, and better wall motion; as we as reductions in post-MI up-regulation of matrix metalloproteinases 2 (MMP-2) and collagen III. In addition, the cardiac up-regulation of B1 receptor and AT1 receptor mRNA were markedly reduced in animals treated with BI 113823, although bradykinin B2 receptor and angiotensin 1 converting enzyme (ACE1) mRNA expression were not significantly affected by B1 receptor blockade.

Conclusions/significance: The present study demonstrates that treatment with the novel B1 receptor antagonist, BI-113823 improves post-MI cardiac function and does not influence the cardiovascular effects of AT1 receptor antagonist following MI.

Citing Articles

Kinins: Locally formed peptides during inflammation with potential use in tissue regeneration.

Martins L, Bader M, Bosco Pesquero J Inflamm Res. 2023; 72(10-11):1957-1963.

PMID: 37750921 DOI: 10.1007/s00011-023-01799-9.

Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade.

Rampa D, Murugesan P, Chao H, Feng H, Dai W, Lee D Respir Res. 2021; 22(1):281.

PMID: 34717626 PMC: 8557528. DOI: 10.1186/s12931-021-01875-w.

Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?.

Gouda A, Megarbane B Drug Dev Res. 2020; 82(1):38-48.

PMID: 32761647 PMC: 7436322. DOI: 10.1002/ddr.21732.

Methanol Extract of Leaves Attenuate Pain via the Modulation of Opioid/NO-Mediated Pathway.

Zakaria Z, Roosli R, Marmaya N, Omar M, Basir R, Somchit M Biomolecules. 2020; 10(2).

PMID: 32059475 PMC: 7072186. DOI: 10.3390/biom10020280.

Exercise training can prevent cardiac hypertrophy induced by sympathetic hyperactivity with modulation of kallikrein-kinin pathway and angiogenesis.

Silva Jr J, Santana E, Manchini M, Antonio E, Bocalini D, Krieger J PLoS One. 2014; 9(3):e91017.

PMID: 24614810 PMC: 3948752. DOI: 10.1371/journal.pone.0091017.

References

Schiller N, Shah P, Crawford M, DeMaria A, Devereux R, FEIGENBAUM H . Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2(5):358-67. DOI: 10.1016/s0894-7317(89)80014-8. View

Xu J, Carretero O, Shesely E, Rhaleb N, Yang J, Bader M . The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol. 2008; 94(3):322-9. PMC: 2719971. DOI: 10.1113/expphysiol.2008.045583. View

Wu D, Qi J . Mechanisms of the beneficial effect of NHE1 inhibitor in traumatic hemorrhage: inhibition of inflammatory pathways. Resuscitation. 2011; 83(6):774-81. DOI: 10.1016/j.resuscitation.2011.11.025. View

Yin H, Chao J, Bader M, Chao L . Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides. 2007; 28(7):1383-9. PMC: 2067250. DOI: 10.1016/j.peptides.2007.05.010. View

Guimaraes J, Vieira M, Camargo M, Maack T . Renal vasoconstrictive effect of kinins mediated by B1-kinin receptors. Eur J Pharmacol. 1986; 130(3):177-85. DOI: 10.1016/0014-2999(86)90266-9. View

Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A . Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes. 2009; 58(6):1373-81. PMC: 2682670. DOI: 10.2337/db08-0329. View

Leeb-Lundberg L, Marceau F, Muller-Esterl W, Pettibone D, Zuraw B . International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005; 57(1):27-77. DOI: 10.1124/pr.57.1.2. View

Krankel N, Katare R, Siragusa M, Barcelos L, Campagnolo P, Mangialardi G . Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res. 2008; 103(11):1335-43. PMC: 2821015. DOI: 10.1161/CIRCRESAHA.108.179952. View

Savvatis K, Westermann D, Schultheiss H, Tschope C . Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Neuropeptides. 2009; 44(2):119-25. DOI: 10.1016/j.npep.2009.11.007. View

10.

Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss H . Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biol Chem. 2008; 389(6):713-8. DOI: 10.1515/BC.2008.070. View

11.

MacNeil T, Feighner S, Hreniuk D, Hess J, Van der Ploeg L . Partial agonists and full antagonists at the human and murine bradykinin B1 receptors. Can J Physiol Pharmacol. 1997; 75(6):735-40. View

12.

Whitehurst R, Laskey R, Goldberg R, Herbert D, van Breemen C . Influence of group B streptococci on piglet pulmonary artery response to bradykinin. J Appl Physiol (1985). 1999; 86(1):61-5. DOI: 10.1152/jappl.1999.86.1.61. View

13.

Erdos E, Tan F, Skidgel R . Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension. 2010; 55(2):214-20. PMC: 2814794. DOI: 10.1161/HYPERTENSIONAHA.109.144600. View

14.

Spillmann F, Graiani G, Van Linthout S, Meloni M, Campesi I, Lagrasta C . Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med. 2007; 1(2):235-54. DOI: 10.2217/17460751.1.2.235. View

15.

Stone O, Richer C, Emanueli C, van Weel V, Quax P, Katare R . Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol. 2009; 29(5):657-64. PMC: 2827862. DOI: 10.1161/ATVBAHA.108.182139. View

16.

Parenti A, Morbidelli L, Ledda F, Granger H, Ziche M . The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 2001; 15(8):1487-9. View

17.

Emanueli C, Salis M, Stacca T, Gaspa L, Chao J, Chao L . Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension. 2001; 38(1):136-41. DOI: 10.1161/01.hyp.38.1.136. View

18.

Golias C, Charalabopoulos A, Stagikas D, Charalabopoulos K, Batistatou A . The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin. Hippokratia. 2009; 11(3):124-8. PMC: 2658795. View

19.

Klein J, Gonzalez J, Decramer S, Bandin F, Neau E, Salant D . Blockade of the kinin B1 receptor ameloriates glomerulonephritis. J Am Soc Nephrol. 2010; 21(7):1157-64. PMC: 3152233. DOI: 10.1681/ASN.2009090887. View

20.

Yokoyama T, Nakano M, Bednarczyk J, McIntyre B, ENTMAN M, Mann D . Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997; 95(5):1247-52. DOI: 10.1161/01.cir.95.5.1247. View